IP Library › Granted Patent US 8,956,628
Granted Patent B2
US 8,956,628 · App. 12/334,863 · Granted Feb 17, 2015

Bacteriophage preparations and method of use thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,956,628
App. No.
12/334,863
Granted
Feb 17, 2015
Kind
B2
Abstract

Disclosed herein are purified bacteriophage preparations that effectively lyse a plurality of C. perfringens strains. In one embodiment, a purified bacteriophage preparation includes four or more C. perfringens -specific bacteriophage, wherein each bacteriophage has lytic activity against at least five C. perfringens strains. In another embodiment, the purified bacteriophage preparation includes five or more C. perfringens -specific bacteriophage.

Claims (17)

1. The A purified bacteriophage preparation comprising CPAS-7 (accession number PTA-8479), CPAS-15 (accession number PTA-8480), CPAS-16 (accession number PTA-8481) and CPLV-42 (accession number PTA-8483) wherein each bacteriophage has lytic activity against at least five C. perfringens strains which cause necrotic enteritis in poultry.

2. The purified bacteriophage preparation of claim 1 , wherein the at least five C. perfringens strains comprise ATCC strain 3624 and ATCC strain 9856.

3. The purified bacteriophage preparation of claim 1 wherein the C. perfringens strains comprise at least five of ATCC strain 25768, ATCC strain 3624, ATCC strain 9856, ATCC strain 3628, ATCC strain 13124, ATCC strain PTA-8495, NRRL strain B-50143, NRRL strain B-50144, NRRL strain B-50145, or a combination thereof.

4. The purified bacteriophage preparation of claim 1 wherein the preparation has lytic activity against ATCC strain 25768, ATCC strain 3624, ATCC strain 9856, ATCC strain 3628, ATCC strain 13124, ATCC strain PTA-8495, NRRL strain B-50143, NRRL strain B-50144, NRRL strain B-50145.

5. The purified bacteriophage preparation of claim 4 , wherein the bacteriophage preparation is incapable of infecting at least ten strains of E. coli, L. monocytogenes, S. enterica , and P. aeruginosa.

6. The purified bacteriophage preparation of claim 1 comprising five or more C. perfringens -specific bacteriophage, wherein each bacteriophage has lytic activity against at least five C. perfringens strains.

7. The purified bacteriophage preparation of claim 6 , comprising CPAS-12 (accession number PTA-8479), CPAS-15 (accession number PTA-8480), CPAS-16 (accession number PTA-481), CPLV-42 (accession number PTA-8483) and CPAS-7 (accession number PTA-8482 wherein each bacteriophage has lytic activity against at least five C. perfringens strains which cause necrotic enteritis in poultry.

8. The purified bacteriophage preparation of claim 7 wherein the at least five C. perfringens strains comprise ATCC strain 3624 and ATCC strain 9856.

9. The purified bacteriophage preparation of claim 7 wherein the C. perfringens strains comprise at least five of ATCC strain 25768, ATCC strain 3624, ATCC strain 9856, ATCC strain 3628, ATCC strain 13124, ATCC strain PTA-8495, NRRL strain B-50143, NRRL strain B-50144, NRRL strain B-50145, or a combination thereof.

10. The purified bacteriophage preparation of claim 7 wherein the preparation has lytic activity against ATCC strain 25768, ATCC strain 3624, ATCC strain 9856, ATCC strain 3628, ATCC strain 13124, ATCC strain PTA-8495, NRRL strain B-50143, NRRL strain B-50144, NRRL strain B-50145.

11. The purified bacteriophage preparation of claim 10 , wherein the bacteriophage preparation is incapable of infecting at least ten strains of E. coli, L. monocytogenes, S. enterica, and P. aeruginosa.

12. The purified bacteriophage preparation of claim 1 , wherein the bacteriophage preparation lyses greater than or equal to 85% of at least 40 screened C. perfringens strains, and wherein the bacteriophage preparation is incapable of infecting at least ten strains of E. coli, L. monocytogenes, S. enterica , and P. aeruginosa.

13. The purified bacteriophage preparation of claim 12 , wherein the bacteriophage preparation lyses greater than or equal to 85% of at least 45 screened C. perfringens strains.

14. The purified bacteriophage preparation of claim 13 , wherein each of the individual C. perfringens -specific bacteriophage lyses 15% to 90% of the screened C. perfringens strains.

15. The purified bacteriophage preparation of claim 1 further comprising a pharmaceutically acceptable excipient.

16. The purified bacteriophage preparation of claim 15 , wherein the pharmaceutically acceptable excipient is a water-conditioning agent.

17. The purified bacteriophage preparation of claim 16 , wherein the water-conditioning agent is a 50mM citrate-phosphate-thiosulfate buffer comprising about 40 mg sodium thiosulfate, 6.0 gm disodium phosphate (anhydrous), 1.1 gm citric acid (anhydrous) per liter of deionized water, pH 7.0, added at a 1:10 or greater ratio.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2015
From: ZOETIS PRODUCTS LLC
To: ZOETIS SERVICES LLC
Reel/Frame 035623/0776 →